Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On May 23, 2021, the board of directors of Adamis Pharmaceuticals Corporation (the Company") designated and appointed David C. Benedicto, the Company's senior director of accounting and controller, as the Company's principal accounting officer; previously, Robert O. Hopkins, the Company's chief financial officer, served as the Company's principal accounting officer. Mr. Benedicto, 60, joined the Company in December 2014, as accounting manager. Mr. Benedicto, a CPA and CMA (Certified Management Accountant), earned a Bachelor's degree in Commerce from the University of Saint La Salle, and an M.B.A. from the University of the Redlands. The selection of Mr. Benedicto to serve as principal accounting officer was not made pursuant to any arrangement or understanding with any other person. The Company will enter into the Company's form of indemnity agreement with Mr. Benedicto. There are no family relationships between Mr. Benedicto and any director or executive officer of the Company, and, except as set forth above, Mr. Benedicto does not have any other direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits








Exhibit No.   Description

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses